Compare CBIO & BBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | BBW |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Recreational Games/Products/Toys |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.5M | 444.3M |
| IPO Year | 2013 | 2004 |
| Metric | CBIO | BBW |
|---|---|---|
| Price | $17.14 | $38.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $26.67 | ★ $67.71 |
| AVG Volume (30 Days) | ★ 283.5K | 257.9K |
| Earning Date | 04-29-2026 | 05-28-2026 |
| Dividend Yield | N/A | ★ 2.51% |
| EPS Growth | N/A | ★ 5.00 |
| EPS | N/A | ★ 1.45 |
| Revenue | $18,500.00 | ★ $357,866,000.00 |
| Revenue This Year | N/A | $5.63 |
| Revenue Next Year | $279.20 | $4.62 |
| P/E Ratio | ★ N/A | $26.06 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.72 | $29.35 |
| 52 Week High | $27.41 | $75.77 |
| Indicator | CBIO | BBW |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 69.27 |
| Support Level | $17.02 | $35.71 |
| Resistance Level | $17.80 | $39.83 |
| Average True Range (ATR) | 1.12 | 1.51 |
| MACD | 0.21 | 0.33 |
| Stochastic Oscillator | 83.78 | 71.79 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments: Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, U.K., Ireland, and two e-commerce sites, the international franchising segment includes royalties and product and fixture sales from other international operations under franchise agreements, and the commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.